WebFeb 28, 2024 · Developer Incanthera Class Antineoplastics; Colchicum alkaloids; Drug conjugates; Peptides Mechanism of Action Vascular disrupting agents Orphan Drug Status No New Molecular Entity Yes Highest Development Phases No development reported Breast cancer; Colorectal cancer; Lung cancer; Prostate cancer Most Recent Events WebINCANTHERA PLC Company number 11026926 Follow this company File for this company Overview Filing history People Registers More Registered office address 76 King Street, …
Incanthera - Crunchbase Company Profile & Funding
WebDeveloped by Prof Robert Falconer, Prof Paul Loadman and jointly funded by Cancer Research UK and Yorkshire Cancer Research the technology formed the basis for the launch of Incanthera Ltd (now plc), an ICT/University of Bradford spin-out company and now licenced to Ellipses Pharma. WebIncanthera Ltd (Incanthera) is a biopharmaceutical company that discovers and develops therapeutic products for the treatment of cancer. The companys drug candidates under development include ICT2588, a vascular disrupting agent, based on the tumor-blasting technology; and ICT03 Es5, a targeted bioreductive agent; which are targeted at ... raba kistner houston tx
Inc.anthera Ltd Company Profile- Outlook, Business Segments ...
WebNov 8, 2015 · This report provides comprehensive information on the current therapeutic developmental pipeline of Incanthera Ltd.’s, complete with comparative analysis at … WebApr 10, 2024 · Incanthera PLC is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops innovative solutions... WebThe pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. shiv icon